CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
University of California, San Francisco
Institute of Hematology & Blood Diseases Hospital, China
Fondazione Italiana Linfomi - ETS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Charite University, Berlin, Germany
ImmunityBio, Inc.
Assistance Publique - Hôpitaux de Paris
Rigshospitalet, Denmark
City of Hope Medical Center
Fondazione Italiana Linfomi - ETS
University of Miami
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The Royal Wolverhampton Hospitals NHS Trust
M.D. Anderson Cancer Center
Beijing Tongren Hospital
Fred Hutchinson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Dizal Pharmaceuticals
University of Pennsylvania
University of Wisconsin, Madison
ASL Lecce
Fondazione Italiana Linfomi - ETS
Eli Lilly and Company
Baylor College of Medicine
Amgen
Baylor College of Medicine
Rennes University Hospital
Baptist Health South Florida
PETHEMA Foundation
TORL Biotherapeutics, LLC
Cancer Research UK
M.D. Anderson Cancer Center
Novartis
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Novartis
Ascentage Pharma Group Inc.
St. Jude Children's Research Hospital
International Food Policy Research Institute
Hutchmed
Center for Health Sciences, Serbia
St. Jude Children's Research Hospital
Canadian Cancer Trials Group
Washington University School of Medicine